TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Intradialytic Nutritional Supplementation in Dialysis Patients
Brief Summary: In this study, the investigators hypothesize that long-term administration of adequate intradialytic oral nutritional supplementation will increase visceral protein concentrations and somatic protein stores in malnourished chronic hemodialysis patients.


Options:
A: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: activity group; Type: EXPERIMENTAL; Interventions: Device: Exercise training in addition to nutritional support | Intervention Type: DEVICE; Name: Exercise training in addition to nutritional support; Assigned to Arm(s): activity group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: pentoxiphylline, Dietary Supplement: Nepro, Dietary Supplement: anti-inflammatory module (similar to Oxepa) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nepro, Dietary Supplement: anti-inflammatory module (similar to Oxepa), Drug: Placebo pill imitating pentoxiphylline | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: pentoxiphylline, Dietary Supplement: Placebo to imitate Nepro, Dietary Supplement: Placebo to imitate anti-inflammatory module (similar to Oxepa) | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill imitating pentoxiphylline, Dietary Supplement: Placebo to imitate Nepro, Dietary Supplement: Placebo to imitate anti-inflammatory module (similar to Oxepa) | Intervention Type: DRUG; Name: pentoxiphylline; Assigned to Arm(s): A, C | Intervention Type: DIETARY_SUPPLEMENT; Name: Nepro; Assigned to Arm(s): A, B | Intervention Type: DIETARY_SUPPLEMENT; Name: anti-inflammatory module (similar to Oxepa); Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Placebo pill imitating pentoxiphylline; Assigned to Arm(s): B, D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo to imitate Nepro; Assigned to Arm(s): C, D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo to imitate anti-inflammatory module (similar to Oxepa); Assigned to Arm(s): C, D
C: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care | Arm Label: Nepro with Carb Steady; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nepro with Carb Steady | Intervention Type: DIETARY_SUPPLEMENT; Name: Nepro with Carb Steady; Assigned to Arm(s): Nepro with Carb Steady | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nepro nutritional supplement | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Nepro nutritional supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Yoga-Based Cancer Rehabilitation Program
Brief Summary: This clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.


Options:
A: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)
B: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
C: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
D: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Yoga-Based Cancer Rehabilitation Program
Brief Summary: This clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4
B: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
C: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)
D: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Yoga-Based Cancer Rehabilitation Program
Brief Summary: This clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.


Options:
A: Arm Label: Yoga Intervention (YOCAS); Type: EXPERIMENTAL; Interventions: Procedure: Yoga Intervention (YOCAS) | Arm Label: Standard Care Control Condition; Type: EXPERIMENTAL; Interventions: Procedure: Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Standard Care Control Condition; Assigned to Arm(s): Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Yoga Intervention (YOCAS); Assigned to Arm(s): Yoga Intervention (YOCAS)
B: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2
D: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TRIGR - Trial to Reduce IDDM in the Genetically at Risk
Brief Summary: The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to breast feed their infants for as long as possible. Prior to birth, the child was randomly assigned to receive one of two infant formulas, should formula be required prior to 8 months of age. The study determined whether weaning to a possibly protective infant formula decreases these children's chances of developing diabetes - as it does in the animal models for diabetes.


Options:
A: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3
C: Arm Label: extensively hydrolyzed casein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Arm Label: cow's milk based infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: dietary intervention; Assigned to Arm(s): cow's milk based infant formula, extensively hydrolyzed casein formula
D: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.
Brief Summary: AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: liposomal daunorubicin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anthracyclines | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: 2-CDA | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: AI | Intervention Type: DRUG; Name: Anthracyclines; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: liposomal daunorubicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 2-CDA; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AI; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cytosin-Arabinosid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: All-trans Retinoid acid; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A
D: Arm Label: Cytarabine low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Arm Label: Cytarabine intermediate dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Cytarabine intermediate dose, Cytarabine low dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
Brief Summary: The purpose of this study is to determine whether combined mortality and hospitalization in heart failure patients receiving optimal pharmacologic therapy can be reduced by combining optimal pharmacologic therapy and 1) biventricular pacing therapy alone or 2) biventricular pacing with defibrillation.


Options:
A: Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: defibrillators, implantable; Assigned to Arm(s): N/A
B: Arm Label: Traditional ICD Programming; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional ICD Programming | Arm Label: Ultra Conservative ICD Programming; Type: EXPERIMENTAL; Interventions: Other: Ultra Conservative ICD Programming | Intervention Type: OTHER; Name: Ultra Conservative ICD Programming; Assigned to Arm(s): Ultra Conservative ICD Programming | Intervention Type: OTHER; Name: Traditional ICD Programming; Assigned to Arm(s): Traditional ICD Programming
C: Arm Label: Cohort A (longitudinal); Type: N/A; Interventions: N/A | Arm Label: Cohort B (6 Month); Type: N/A; Interventions: N/A | Arm Label: Cohort C (18 Month); Type: N/A; Interventions: N/A
D: Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy with & without defibrillator; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS
Brief Summary: Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?


Options:
A: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS
Brief Summary: Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?


Options:
A: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
B: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted
C: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group
D: Arm Label: Feedback; Type: EXPERIMENTAL; Interventions: Other: personalized repeated feedback approach | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: personalized repeated feedback approach; Assigned to Arm(s): Feedback

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS
Brief Summary: Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?


Options:
A: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
B: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine
C: Arm Label: Group A(heparin group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Group A(heparin group)
D: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS
Brief Summary: Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?


Options:
A: Arm Label: Group A(heparin group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Group A(heparin group)
B: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
C: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
D: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Brief Summary: This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate HCl (Concerta) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylphenidate HCl (Concerta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A

Answer: C